Abstract Details

Title Cerebral Microbleeds Are More Frequent in Ischemic Stroke Than in Transient Ischemic Attack

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P03 - (-)

Poster/Presentation
Number 159

Objective

Background BACKGROUND: Antithrombotic treatments are frequently prescribed after an ischemic stroke, but one of their main adverse effects is the increase in the risk of hemorrhagic stroke moreover, the presence of microbleeds also increases this risk. The aim of this study was to prove the prevalence of these lesions in patients with ischemic stroke and transient ischemic attack (TIA).

Design/Methods DESIGN/METHODS: Patients with ischemic stroke were prospectively included in the study, MRI, including T2, fluid-attenuated inversion recovery, and gradient-echo MRI sequences were performed.

Results RESULTS: Four hundred and sixty three patients were included, 75% ischemic strokes and 25% TIA. Microbleeds were found in 25.72% of the patients who has suffer ischemic stroke , but only in 7.69% of the patients withTIA (p < 0.0001). There were no differences in vascular risk factor profile between both groups. White matter disease on T2 MRI was found in 44.8 % of stroke patients and 17% of TIA (p 0.0001).We observed that, Patients with microbleeds trend to be older (mean age 83 ± 6 vs 73 ± 10 years; p 0.00001).

Conclusions CONCLUSIONS: Microbleeds and severe white matter disease are frequently found in ischemic stroke but rare in TIA, and this fact is not attributable to differences in vascular risk factor profile. This finding has implications for the safety of antithrombotic therapy in both groups. We consider that Microbleeds may also be a new marker for severe microvascular disease with increased risk of permanent cerebral infarction.

Authors/Disclosures
PRESENTER	No disclosure on file
Maria C. Zurru, MD	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Kevin M. Flanigan, MD, FAAN (Nationwide CHildrens Hospital)	Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Solid. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Armatus. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avidity. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne. The institution of Dr. Flanigan has received research support from Ultragenyx . The institution of Dr. Flanigan has received research support from Solid Biosciences. The institution of Dr. Flanigan has received research support from Dyne Therapeutics. The institution of Dr. Flanigan has received research support from Avidity.
Edgardo Cristiano, MD (Hospital Italiano De Buenos Aires)	Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.

��ɫ��

��ɫ��